Targefrin: A Potent Agent Targeting the Ligand Binding Domain of EphA2

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• EphA2 receptor tyrosine kinase (RTK) overexpression correlates with poor prognosis and aggressive metastatic cancers.
• Targeting EphA2 presents a promising strategy for cancer therapy.

Purpose of the Study:

• To develop and characterize a novel agent targeting the EphA2 receptor.
• To evaluate the efficacy of this agent in preclinical cancer models.

Main Methods:

• X-ray crystallography guided design of an agonistic peptide.
• Isothermal titration calorimetry to determine binding affinity (dissociation constant = 21 nM).
• Biochemical and cell-based assays to assess EphA2 activity and receptor internalization/degradation.
• Chemotherapy conjugation and in vivo efficacy studies in mouse xenograft models.

Main Results:

• The novel agent, targefrin, binds EphA2-LBD with high affinity (21 nM Kd) and potent biochemical inhibition (10.8 nM IC50).
• Dimeric versions of the agent effectively induce EphA2 internalization and degradation in pancreatic cancer cell lines.
• Chemotherapy-conjugated agents demonstrate targeted delivery and efficacy in a pancreatic cancer xenograft model.

Conclusions:

• The developed agent shows significant potential for targeting EphA2 in aggressive cancers.
• Further development of these EphA2-targeting agents could lead to innovative cancer therapeutics.